UK markets open in 7 hours 1 minute
  • NIKKEI 225

    29,088.08
    +223.76 (+0.78%)
     
  • HANG SENG

    29,098.29
    -138.51 (-0.47%)
     
  • CRUDE OIL

    67.49
    +1.40 (+2.12%)
     
  • GOLD FUTURES

    1,705.20
    +6.70 (+0.39%)
     
  • DOW

    31,496.30
    +572.20 (+1.85%)
     
  • BTC-GBP

    37,149.86
    +1,666.61 (+4.70%)
     
  • CMC Crypto 200

    1,039.23
    +96.06 (+10.18%)
     
  • ^IXIC

    12,920.15
    +196.65 (+1.55%)
     
  • ^FTAS

    3,771.73
    -20.36 (-0.54%)
     

Verana Health Announces Real-World Data and Data Science Collaboration Agreement with Janssen

·2-min read

Verana Health, a leader in transforming clinical data into actionable real-world evidence, today announced a research collaboration agreement with Janssen Research & Development, LLC (Janssen). The research collaboration will focus on curating real-world data and driving data science applications in the areas of ophthalmology and urology.

Through the agreement, Verana Health aims to further advance the utilization of real-world evidence and data science to inform research and development. Verana Health will provide data-driven support in this area to enable a deeper understanding of new disease areas of interest, inform study design, and enhance the execution of clinical trials.

By generating real-world evidence in the retinal and broader ophthalmology space through the American Academy of Ophthalmology IRIS® Registry (Intelligent Research in Sight), Verana Health hopes to contribute to the development of new ophthalmic therapies and treatments. Verana Health will analyze real-world data to characterize baseline patient attributes, disease progression, and treatment-based outcomes for patients being treated for diabetic macular edema, a complication of diabetes that impacts 750,000 Americans and may lead to severe vision loss. Currently, real-world evidence on this population of patients—including treatment patterns and outcomes—is limited.

In urology, the research collaboration will focus on early-stage prostate cancer. The first phase of this pilot will support curating and evaluating de-identified data from a small subset of patients in the American Urological Association Quality (AQUA) Registry.

"We are incredibly excited to collaborate with Janssen R&D to support innovation in ophthalmology and urology," said Hylton Kalvaria, Senior Vice President, Commercial and Strategic Partnerships for Verana Health. "Characterizing early-stage prostate cancer has become increasingly important to improve patient outcomes. The ability to characterize early-stage urologic cancers is missing from many oncology databases, so we hope that Verana Health’s ability to fill this void can help thousands of men diagnosed with prostate cancer every year."

About Verana Health:

Verana Health partners with leading medical associations to transform clinical data into actionable real-world evidence. These partnerships enable Verana Health to harness the comprehensive data found in qualified clinical data registries and other specialty data sources to accelerate medical research and enhance patient care. Learn more at veranahealth.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210127005518/en/

Contacts

Media Contacts:
David Cirilli
(646) 727-0063
dave.cirilli@veranahealth.com

Michele Gray
(917) 449-9250
michele_gray@me.com